All In Biotech

Drug Trial Radar · NCT07639905

A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets

A Single-center, Single-dose, Randomized, Open-label, Two-period, Crossover Clinical Study on the Bioavailability and Safety of the New and Old Formulations HRS-2189 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jun 19, 2026

Primary completion

Aug 6, 2026

Study completion Aug 6, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, single-dose, randomized, open-label, two-period, crossover phase I clinical trial, comparing the bioavailability and safety of the new and old processes of HRS-2189 tablets in healthy subjects.

Conditions

  • Malignant Solid Tumor

Interventions

  • HRS-2189 TabletDrug

    HRS-2189 tablet, oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximum plasma concentration (Cmax)Time frame: Day1 - Day37.
  2. From time 0 to the area under the blood drug concentration-time curve corresponding to the last quantifiable concentration (AUC0-t)Time frame: Day1 - Day37.
  3. Area under the concentration curve from time 0 to extrapolated infinite time (AUCinf)Time frame: Day1 - Day37.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.